Synaptogenix Current Ratio 2020-2025 | TAOX
Synaptogenix current ratio from 2020 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Synaptogenix Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2025-03-31 |
$0.02B |
$0.00B |
72.70 |
| 2024-12-31 |
$0.02B |
$0.00B |
17.47 |
| 2024-09-30 |
$0.02B |
$0.00B |
65.36 |
| 2024-06-30 |
$0.03B |
$0.01B |
2.98 |
| 2024-03-31 |
$0.03B |
$0.01B |
4.58 |
| 2023-12-31 |
$0.03B |
$0.00B |
7.14 |
| 2023-09-30 |
$0.03B |
$0.00B |
17.79 |
| 2023-06-30 |
$0.03B |
$0.00B |
12.05 |
| 2023-03-31 |
$0.04B |
$0.00B |
28.59 |
| 2022-12-31 |
$0.04B |
$0.00B |
29.39 |
| 2022-09-30 |
$0.03B |
$0.00B |
39.98 |
| 2022-06-30 |
$0.03B |
$0.00B |
47.22 |
| 2022-03-31 |
$0.03B |
$0.00B |
48.31 |
| 2021-12-31 |
$0.04B |
$0.00B |
17.80 |
| 2021-09-30 |
$0.03B |
$0.00B |
32.11 |
| 2021-06-30 |
$0.03B |
$0.00B |
42.78 |
| 2021-03-31 |
$0.00B |
|
0.00 |
| 2020-12-31 |
$0.00B |
|
0.00 |
| 2020-09-30 |
$0.00B |
|
0.00 |
| 2020-06-30 |
$0.00B |
|
0.00 |
| 2019-12-31 |
$0.02B |
$0.00B |
37.32 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.011B |
$0.000B |
|
Synaptogenix Inc. is an emerging biopharmaceutical company. It focused on developing therapies for neurodegenerative diseases. The company's lead therapeutic candidate consist Bryostatin-1. Synaptogenix Inc. is based in NEW YORK.
|
